1, for mothers 1, for mothers with HBsAg positive, HBVDNA less than 4 times of 10 and normal liver function in preparation for pregnancy: no drug treatment, regular observation of liver function during pregnancy. 2. For mothers with HBsAg positive, HBeAg positive and HBVDNA greater than 4 times of 10, it is better to lower the HBVDNA to 4 times of 10 with tenbivudine or tenofovir, which have higher pregnancy safety (B grade), so as to greatly reduce the intrauterine infection of fetal hepatitis B virus. If the mother in immune tolerance, after childbirth can stop the drug observation, do not need to continue to take. 2. For newborns 1. For newborns of HBsAg-positive mothers, high-efficiency hepatitis B immunoglobulin should be injected within 12 hours after birth at a dose of ≥100 IU, while 10 μg of recombinant yeast hepatitis B vaccine should be administered at different sites, and the second and third doses of hepatitis B vaccine should be administered at 1 month and 6 months respectively, which can significantly improve the effect of blocking mother-to-child transmission of hepatitis B virus. 2. For those who are immunocompromised or non-responders, the vaccination dose (e.g. 60 μg) and number of doses should be increased; for those who do not respond to the 3-dose immunization program, another 60 μg or 3 20 μg doses of recombinant yeast hepatitis B vaccine can be administered, and the anti-HBs in the serum should be tested 1~2 months after the 2nd hepatitis B vaccination, and if there is still no response, another 60 μg recombinant yeast hepatitis B vaccine can be administered. vaccine.